Avirmax Biopharma Doses First Patient in Phase I/IIa Clinical Trial of ABI-110
Avirmax Biopharma has reached a major milestone in its mission to revolutionize the treatment of wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) by successfully dosing the first patient in the phase I/IIa clinical trial of ABI-110, the company’s first gene therapy drug.
A Milestone in Gene Therapy for Wet AMD
Shawn Liu, PhD, Chief Executive Officer of Avirmax Biopharma, expressed excitement about this breakthrough, stating:
“We are thrilled to announce this significant milestone in the clinical investigation of ABI-110. ABI-110 has the potential to revolutionize the treatment landscape for Wet AMD and PCV.”
How ABI-110 Works
ABI-110 is a proprietary gene therapy that utilizes Avirmax Biopharma's engineered capsid, AAV2.N54, to deliver a therapeutic transgene directly to the macular retina. Unlike existing treatments, which often focus on managing symptoms, ABI-110 targets the genetic root causes of wet AMD.
Key Advantages:
• Durability: Offers the potential for long-lasting therapeutic effects.
• Efficacy: Designed to overcome the limitations of current treatments, providing more robust solutions for patients.
Objectives of the Phase I/IIa Clinical Trial
The ongoing clinical trial aims to evaluate:
1. Safety: Monitoring adverse effects associated with the therapy.
2. Tolerability: Ensuring that the treatment is well-received by patients.
3. Preliminary Efficacy: Assessing the effectiveness of ABI-110 in reducing the progression of Wet AMD and PCV.
The Promise of ABI-110
ABI-110 represents a cutting-edge approach in ophthalmology, with the potential to transform the standard of care for wet AMD and PCV. By addressing the disease at the genetic level, this therapy could offer patients a more durable and effective solution, significantly improving their quality of life.
As this trial progresses, Avirmax Biopharma continues to lead the way in innovative treatments for retinal diseases.
